Death  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01567085 / 2010-019631-35: Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Completed
2
80
Europe, RoW
Eculizumab, Soliris
Alexion Pharmaceuticals
Stage V Chronic Kidney Disease
06/15
05/17
NCT01919346: Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation

Terminated
2
21
US
Eculizumab, Soliris, Normal Saline
Heeger, Peter, M.D., Alexion Pharmaceuticals, Icahn School of Medicine at Mount Sinai
Delayed Graft Function, Kidney Transplantation, Complement Activity
12/17
12/17
NCT01106027: Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

Terminated
1/2
2
US
Eculizumab, Soliris
Mayo Clinic, Alexion Pharmaceuticals
Kidney Transplant
08/16
08/16

Download Options